(Boston Children’s Hospital) A team of researchers from Boston Children’s Hospital, Harvard Medical School and Harvard’s Wyss Institute have adapted their DNA nanoswitch technology — previously demonstrated to aid drug discovery and the measure of biochemical interactions — into a new platform that they call the nanoswitch-linked immunosorbent assay (NLISA) for fast, sensitive and specific protein detection.